Fate Therapeutics (FATE) Projected to Post Earnings on Monday

Fate Therapeutics (NASDAQ:FATE) is projected to post its quarterly earnings results before the market opens on Monday, February 24th. Analysts expect Fate Therapeutics to post earnings of ($0.44) per share and revenue of $1.51 million for the quarter.

Fate Therapeutics Trading Down 8.1 %

Shares of FATE opened at $1.42 on Friday. The stock has a market capitalization of $161.72 million, a P/E ratio of -0.86 and a beta of 2.02. The firm’s fifty day simple moving average is $1.49 and its two-hundred day simple moving average is $2.53. Fate Therapeutics has a 12 month low of $1.04 and a 12 month high of $8.83.

Insider Activity at Fate Therapeutics

In other Fate Therapeutics news, Director Redmile Group, Llc purchased 397,964 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The shares were acquired at an average price of $1.68 per share, with a total value of $668,579.52. Following the transaction, the director now owns 12,884,277 shares in the company, valued at $21,645,585.36. The trade was a 3.19 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.00% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on FATE shares. Wedbush reissued a “neutral” rating and set a $5.00 price objective on shares of Fate Therapeutics in a research report on Tuesday, November 12th. Needham & Company LLC reissued a “hold” rating on shares of Fate Therapeutics in a research report on Tuesday, November 19th. Finally, Bank of America raised shares of Fate Therapeutics from an “underperform” rating to a “neutral” rating in a research report on Monday, November 18th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $6.75.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.